Navigation Links
Essentialis Files Two New Patent Applications for Investigational Compound DCCR

SAN DIEGO, Feb. 29, 2012 /PRNewswire/ -- Essentialis, Inc. announced the February 27, 2012 filing of two new patent applications expanding the patent portfolio claiming its investigational triglyceride-lowering compound DCCR and new methods of using the drug.  The first is a continuation-in-part of a current application that includes data from the recently completed clinical trial, CT013; the second is a patent filing covering certain aspects of the use of DCCR in the treatment of very high triglycerides (VHTG).  The filing is the fourth patent application filed by Essentialis covering DCCR, and has the potential to extend patent protection on the product to 2033.  Essentialis already holds composition of matter protection for DCCR through 2028.

"With our portfolio of issued and pending patents, we already have very solid protection and these new applications will make our protection even stronger," said Aaron D. Berg, President and Chief Executive Officer, Essentialis, Inc. "We are targeting 2015 market availability for DCCR, and it is our hope to receive patent protection through 2033."

Essentialis already has two issued US patents (7,572,789 and 7,799,777) providing composition of matter protection to DCCR to 2028 and two granted European patents (EP1781265 and EP1968601) providing similar protection.  With the recent filings, Essentialis is prosecuting eight US patent applications.  The company is prosecuting these filings in all major pharmaceutical markets.  The current protection on the product includes claims to the active ingredient, pharmaceutical formulations, methods of manufacture, and a wide range of methods to treat multiple diseases.  In particular, the claims cover methods to treat dyslipidemia including co-formulation and co-administration with a range of drugs currently used in the treatment of patients with lipid disorders.  

About DCCR
DCCR is a proprietary crystalline salt of diazoxide in a controlled-release, once-a-day tablet formulation. It is in development for patients with very high triglyceride (TG) levels. Essentialis has completed an End-of-Phase 2 meeting with the FDA and has obtained an SPA covering a pivotal study. Essentialis expects to initiate Phase 3 clinical trials in 2012. DCCR is covered by multiple issued US and granted EU patents, which provide composition of matter protection until 2028. Essentialis has evaluated DCCR in several double-blind, placebo-controlled studies which demonstrated that the drug was well tolerated and that statistical significance for various endpoints was achieved in patients with elevated triglycerides. More than 100,000 patient-years of treatment with diazoxide help support the acceptable safety of DCCR.

About Essentialis, Inc.
Essentialis is a San Diego-headquartered pharmaceutical company focused on the development of breakthrough medicines targeted to the ATP-sensitive potassium channel, a metabolically regulated membrane protein whose modulation has potential to treat and prevent a wide range of cardiovascular and metabolic diseases. For more information visit


Kristie Kuhl 


Aaron Berg 

SOURCE Essentialis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Essentialis Appoints Mahendra G. Shah, Ph.D., to Board of Directors
2. Essentialis Promotes Aaron Berg to Chief Executive Officer
3. Essentialis Strengthens Patent Protection of Its Novel ATP-Sensitive Potassium Channel Opener Portfolio
4. Essentialis to Submit SPA for Hypertriglyceridemia
5. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
6. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
7. Bionovo Files Registration Statement for Offering of Convertible Preferred Stock and Warrants
8. ReBuilder (RBRM) Files Complaints Against Stock Traders
9. Acella Pharmaceuticals, LLC, Files Abbreviated New Drug Application (ANDA) With the U.S. Food & Drug Administration
10. Natural Alternatives International, Inc. Files Patent Infringement Claim Against DNP International Co., Inc.
11. Department of Justice files consent decree of permanent injunction against Ranbaxy
Post Your Comments:
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
Breaking Medicine News(10 mins):